Shenzhen Hepalink Pharmaceutical Group saw the highest growth of 0.99% in patent filings in June and 1.66% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.49%. GlobalData’s DataBook provides a comprehensive analysis of Shenzhen Hepalink Pharmaceutical Group’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
Shenzhen Hepalink Pharmaceutical Group has been focused on protecting inventions in Australia(AU) with three publications in Q2 2024
The Australia(AU) Patent Office dominates the patent grants with nearly 38% of grants. The United States(US), World Intellectual Property Organization(WIPO), Australia(AU), and China(CN) patent Office are among the top ten patent offices where Shenzhen Hepalink Pharmaceutical Group is filings its patents. Among the top granted patent authorities, Shenzhen Hepalink Pharmaceutical Group has 38% of its grants in Australia(AU), 25% in United States(US) and 25% in China(CN).
Roche and Johnson & Johnson could be the strongest competitors for Shenzhen Hepalink Pharmaceutical Group
Patents related to Covid-19 and rare diseases lead Shenzhen Hepalink Pharmaceutical Group's portfolio
Shenzhen Hepalink Pharmaceutical Group has the highest number of patents in Covid-19 followed by, rare diseases. For Covid-19, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Inflammatory bowel disease related patents lead Shenzhen Hepalink Pharmaceutical Group portfolio followed by liver diseases, and neurodegenerative diseases
Shenzhen Hepalink Pharmaceutical Group has highest number of patents in inflammatory bowel disease followed by liver diseases, neurodegenerative diseases, atherosclerosis, and inflammation. For inflammatory bowel disease, nearly 20% of patents were filed and 5% of patents were granted in Q2 2024.
For comprehensive analysis of Shenzhen Hepalink Pharmaceutical Group's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
